BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q4 2023
Top Holdings84 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
INCYTE CORP | 36.2M | $2.3B | 25.8% | $85.04 | -26.16% | 20 qtrssince 2019-Q1 | Increased 62 |
BEIGENE LTD-ADR | 10.6M | $1.9B | 21.7% | $149.13 | +20.94% | 20 qtrssince 2019-Q1 | Decreased 0 |
ACADIA Pharmaceuticals Inc. | 42.9M | $1.3B | 15.3% | $27.50 | +13.86% | 20 qtrssince 2019-Q1 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 2M | $455.8M | 5.2% | $142.75 | +62.09% | 20 qtrssince 2019-Q1 | Increased 76 |
RHYTHM PHARMACEUTICALS INC | 6.4M | $294.1M | 3.3% | $23.84 | +92.81% | 20 qtrssince 2019-Q1 | Decreased 0 |
MIRATI THERAPEUTICS INC | 4.1M | $242.1M | 2.8% | — | — | 20 qtrssince 2019-Q1 | Increased 85 |
IMMUNOCORE HLDGS PLC | 2.5M | $172.2M | 2.0% | $43.20 | +58.15% | 12 qtrssince 2021-Q1 | Unchanged 0 |
KYMERA THERAPEUTICS INC | 6M | $152.7M | 1.7% | $27.87 | -8.66% | 14 qtrssince 2020-Q3 | Increased 59 |
REVOLUTION MEDICINES INC | 5.1M | $147.7M | 1.7% | $25.88 | +10.84% | 12 qtrssince 2021-Q1 | Increased 75 |
| 300M | $131.2M | 1.5% | — | — | — | Unchanged 0 | |
ABCELLERA BIOLOGICS INC | 22.9M | $130.8M | 1.5% | $21.87 | -73.89% | 13 qtrssince 2020-Q4 | Increased 53 |
ROIVANT SCIENCES LTD | 7.6M | $85.3M | 1.0% | $9.27 | +21.19% | 5 qtrssince 2022-Q4 | Decreased 0 |
Replimune Group, Inc. | 9.5M | $80.5M | 0.9% | $13.95 | -39.57% | 15 qtrssince 2020-Q2 | Increased 68 |
ENTRADA THERAPEUTICS INC | 4.9M | $73.4M | 0.8% | $18.19 | -17.04% | 9 qtrssince 2021-Q4 | Unchanged 0 |
Ultragenyx Pharmaceutical, Inc. | 1.5M | $70.1M | 0.8% | $72.21 | -33.78% | 13 qtrssince 2020-Q4 | Increased 45 |
CEREVEL THERAPEUTICS HLDNG I | 1.6M | $67.8M | 0.8% | — | — | 1 qtr | New 58 |
IMMATICS N.V | 5.8M | $61.5M | 0.7% | $11.00 | -4.24% | 14 qtrssince 2020-Q3 | Increased 43 |
BIOCRYST PHARMACEUTICALS INC | 10.1M | $60.7M | 0.7% | $7.50 | -20.09% | 20 qtrssince 2019-Q1 | Decreased 0 |
ARGENX SE - ADR | 151,215 | $57.5M | 0.7% | $138.29 | +175.10% | 20 qtrssince 2019-Q1 | Unchanged 0 |
DENALI THERAPEUTICS INC | 2.6M | $56M | 0.6% | $24.90 | -13.83% | 16 qtrssince 2020-Q1 | Increased 47 |
BAKER BROS. ADVISORS LP manages $8.8B across 84 positions as of Q4 2023. Top holdings: INCY (25.8%), ONC (21.7%), ACAD (15.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3.5/5.0.
Active quarter - 5 new positions, 22 exits, 23 increased. Top move: MRTX (INCREASED, conviction 85). Portfolio: $8.8B across 84 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer